Kodiak Sciences Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KOD research report →
Companykodiak.com
Kodiak Sciences Inc. , a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
- CEO
- Victor Perlroth
- IPO
- 2018
- Employees
- 109
- HQ
- Palo Alto, CA, US
Price Chart
Valuation
- Market Cap
- $1.92B
- P/E
- -9.71
- P/S
- 0.00
- P/B
- 19.98
- EV/EBITDA
- -8.81
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -253.85%
- ROIC
- -87.69%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-229,967,000 · -30.51%
- EPS
- $-4.32 · -28.96%
- Op Income
- $-234,388,000
- FCF YoY
- -15.97%
Performance & Tape
- 52W High
- $47.84
- 52W Low
- $3.26
- 50D MA
- $37.20
- 200D MA
- $23.71
- Beta
- 2.32
- Avg Volume
- 1.07M
Get TickerSpark's AI analysis on KOD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 15, 26 | BORGESON JOHN A. | other | 28,614 |
| Apr 15, 26 | BORGESON JOHN A. | other | 28,614 |
| Apr 2, 26 | BORGESON JOHN A. | other | 30,000 |
| Apr 2, 26 | BORGESON JOHN A. | sell | 12,692 |
| Apr 2, 26 | BORGESON JOHN A. | sell | 12,477 |
| Apr 2, 26 | BORGESON JOHN A. | sell | 4,231 |
| Apr 2, 26 | BORGESON JOHN A. | sell | 600 |
| Apr 2, 26 | BORGESON JOHN A. | other | 30,000 |
| Mar 25, 26 | PERLROTH VICTOR | other | 300,000 |
| Mar 25, 26 | PERLROTH VICTOR | other | 300,000 |
Our KOD Coverage
We haven't published any research on KOD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KOD Report →